These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 86628)

  • 1. [Clinical experience with NK 631 in malignant tumors of skin (author's transl)].
    Nobe O; Kubo H; Yoshii K; Tashiro M
    Jpn J Antibiot; 1979 Mar; 32(3):463-9. PubMed ID: 86628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical experience with NK 631 (pepleomycin) for malignant tumors of skin (author's transl)].
    Seki T; Shimada S; Ohara K
    Jpn J Antibiot; 1979 Feb; 32(2):278-81. PubMed ID: 86624
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical application of NK 631, a new derivative of bleomycin (author's transl)].
    Asahi M
    Jpn J Antibiot; 1979 Jul; 32(7):744-50. PubMed ID: 90742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical effects of NK 631, a new bleomycin derivative, in treatment of oral cancer (author's transl)].
    Kajiyama M; Dohjyo M; Ohno A; Nagasaka K; Yamaguma M; Okabe T; Terasaka S
    Jpn J Antibiot; 1979 Jan; 32(1):129-37. PubMed ID: 84883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of PEP bleomycin studies in Japan.
    Ikeda S; Miyasato H; Nakayama H; Tajima K; Sato A
    Recent Results Cancer Res; 1981; 76():41-60. PubMed ID: 6165056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical effects of NK 631 in malignant tumors of the oral cavity (author's transl)].
    Kawahira K; Dohhara Y; Sugihara K; Yamada K; Fujinami Y; Saku T; Yamashita S
    Jpn J Antibiot; 1979 Jan; 32(1):138-48. PubMed ID: 84884
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug therapy of malignant tumors of the skin. Bleomycin].
    Ocaña Sierra J
    Actas Dermosifiliogr; 1975; 66(3-4):159-78. PubMed ID: 51577
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical experience with pepleomycin (NK 631) (author's transl)].
    Hashimoto K; Shioda S; Amagasa T; Shimizu M; Sato O; Ito H; Fujibayashi T; Soda T
    Jpn J Antibiot; 1979 Mar; 32(3):451-62. PubMed ID: 86627
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical application of NK 631 to head-and-neck cancers (author's transl)].
    Ogawa Y; Omata T; Imaizumi H; Shiga H; Ouchi J
    Jpn J Antibiot; 1979 Jan; 32(1):115-20. PubMed ID: 84881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment with NK 631 (new bleomycin analog) of oral and maxillofacial cancer (author's transl)].
    Nakanishi K; Miki T; Adachi K; Teranobu O; Shimada K
    Jpn J Antibiot; 1979 Feb; 32(2):282-90. PubMed ID: 86625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experiences with pepleomycin (NK 631) (author's transl)].
    Kusakari J; Sato Y; Saijo S; Tomioka S; Kawamoto K
    Jpn J Antibiot; 1978 Nov; 31(11):659-63. PubMed ID: 83402
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical effects of NK 631 (pepleomycin) against malignant tumors of the head and neck (author's transl)].
    Satoh F; Saitoh H; Mizukoshi O
    Jpn J Antibiot; 1979 Jul; 32(7):751-5. PubMed ID: 90743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I and phase II studies of a new bleomycin (pepleomycin) (author's transl)].
    Miura T; Katayama K; Wada T
    Jpn J Antibiot; 1979 Feb; 32(2):265-77. PubMed ID: 86623
    [No Abstract]   [Full Text] [Related]  

  • 14. [Preoperative application of NK 631 for carcinoma of oral cavity (author's transl)].
    Yamamoto E; Sunakawa H; Kohama GI
    Jpn J Antibiot; 1979 Feb; 32(2):253-8. PubMed ID: 86621
    [No Abstract]   [Full Text] [Related]  

  • 15. [Topical chemotherapy for carcinoma of the skin (author's transl)].
    Miki Y; Kawatsu T; Matsuda H; Yamada T; Kahata A
    Jpn J Antibiot; 1975 Feb; 28(1):37-43. PubMed ID: 47924
    [No Abstract]   [Full Text] [Related]  

  • 16. [Primary effect of NK 631 against head-and-neck cancers (author's transl)].
    Takata K; Honda T
    Jpn J Antibiot; 1979 Jan; 32(1):106-14. PubMed ID: 84880
    [No Abstract]   [Full Text] [Related]  

  • 17. [Studies on the clinical effect of NK 631 for oral-cavity cancers (author's transl)].
    Ohashi Y; Abe M; Saito K; Mizutani H; Onishi S; Ueda N
    Jpn J Antibiot; 1979 Feb; 32(2):259-64. PubMed ID: 86622
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical application of NK-631, a new bleomycin to head-and-neck malignant tumors (author's transl)].
    Makimoto K; Nagahara K
    Jpn J Antibiot; 1979 Jan; 32(1):121-8. PubMed ID: 84882
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of head and neck tumors by the combination of bleomycin, methotrexate, cyclophosphamide and corticoid (author's transl)].
    Mamede RC; Mascarenhas LG
    Ann Otolaryngol Chir Cervicofac; 1980; 97(10-11):949-57. PubMed ID: 6163387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Histological appearances of cancer of the head and neck treated with pepleomycin (NK 631) (author's transl)].
    Matsumura Y; Nomura Y; Eguchi S; Yanagita T
    Jpn J Antibiot; 1978 Nov; 31(11):651-8. PubMed ID: 83401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.